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 Adverse drug reactions (ADRs) remain a challenge in modern 
healthcare, particularly given the increasing complexity of 
therapeutics, an ageing population and rising multimorbidity. 
This article summarises some of the key facts about ADRs and 
explores aspects relating to their prevention, diagnosis, report-
ing and management in current clinical practice. 
 Basics of adverse drug reactions 
 An adverse drug reaction (ADR) can be defined as ‘an 
appreciably harmful or unpleasant reaction resulting from an 
intervention related to the use of a medicinal product; adverse 
effects usually predict hazard from future administration 
and warrant prevention, or specific treatment, or alteration 
of the dosage regimen, or withdrawal of the product’. 1 Since 
2012, the definition has included reactions occurring as a 
result of error, misuse or abuse, and to suspected reactions 
to medicines that are unlicensed or being used off-label 
in addition to the authorised use of a medicinal product 
in normal doses. 2 While this change potentially alters the 
reporting and surveillance carried out by manufactures and 
medicines regulators, in clinical practice it should not affect 
our approach to managing ADRs. 
 Seminal research undertaken in the late 20th and early 21st 
century in the USA and the UK demonstrated that ADRs are a 
common manifestation in clinical practice, including as a cause 
of unscheduled hospital admissions, occurring during hospital 
admission and manifesting after discharge. 3–6 The incidence 
of ADRs has remained relatively unchanged over time, with 
research suggesting that between 5 and 10% of patients may 
suffer from an ADR at admission, during admission or at 
discharge, despite various preventative efforts. Inevitably, the 
event frequency is associated with the method used to identify 
such events and the majority of ADRs do not cause serious 
systemic manifestations. Nevertheless, this frequency of 
potential harm needs to be considered carefully because it has 
associated morbidity and mortality, can be financially costly 
and has a potentially negative effect on the prescriber-patient 
relationship. 
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 Adverse drug reactions 
 Medicines that have been particularly implicated in 
ADR-related hospital admissions include antiplatelets, 
anticoagulants, cytotoxics, immunosuppressants, diuretics, 
antidiabetics and antibiotics. Fatal ADRs, when they occur, 
are often attributable to haemorrhage, the most common 
suspected cause being an antithrombotic/anticoagulant 
co-administered with a non-steroidal anti-inflammatory drug 
(NSAID). 7 
 Classiﬁcation of adverse drug reactions 
 Traditionally ADRs have been classified into two types: 
 1  Type A reactions – sometimes referred to as augmented 
reactions – which are ‘dose-dependent’ and predictable on 
the basis of the pharmacology of the drug 
 2  Type B reactions – bizarre reactions – which are idiosyncratic 
and not predictable on the basis of the pharmacology. 8 
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 Key points 
 Adverse drug reactions (ADRs) – unintended, harmful events 
attributed to the use of medicines – occur as a cause of 
and during a significant proportion of unscheduled hospital 
admissions. 
 A careful medication history can assist a prescriber in 
understanding the patient's previous experiences with drug 
treatment particularly in identifying previous ADRs that may 
preclude re-exposure to the drug. 
 Preventing ADRs depends on avoiding treatment in cohorts 
of patients who are at increased susceptibility or providing 
treatment under a therapeutic plan that reduces the risk 
of an adverse effect (eg co-administration of other drugs, 
monitoring blood test results). 
 Spontaneous reporting (using the Yellow Card Scheme in the 
UK) based on the suspicion of an ADR is an important part of 
pharmacovigilance but, overall, ADRs are vastly underreported 
across healthcare settings and sectors. If in doubt, it is best to 
submit a report. 
 KEYWORDS :  Adverse drug reactions ,  clinical pharmacology , 
 drug-related side effects and adverse reactions , 
 pharmacovigilance ,  adverse drug reaction reporting systems ■
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 Although still widely quoted, this basic classification does 
not work for all ADRs, such as with chronic adverse effects 
associated with cumulative drug exposure (eg osteoporosis with 
long-term corticosteroid treatment) or withdrawal reactions (eg 
rebound hypertension with centrally-acting antihypertensive 
cessation). An alternative and perhaps more comprehensive 
classification scheme is ‘DoTS’, which classifies reactions 
dependent on the  Do se of the drug, the  T ime course of the 
reaction and relevant  S usceptibility factors (such as genetic, 
pathological and other biological differences). 9 As well as 
classifying reactions, DoTS has the advantage of being helpful 
to consider the diagnosis and prevention of ADRs in practice. 
 Preventing adverse drug reactions 
 While some ADRs are unpredictable – such as anaphylaxis in a 
patient after one previous uneventful exposure to a penicillin-
containing antibiotic – many are preventable with adequate 
foresight and monitoring. Preventability (or avoidability) 
usually refers to when the drug treatment plan is inconsistent 
with current evidence-based practice or is unrealistic when 
taking known circumstances into account. 10 Epidemiological 
studies tend to find that between a third and a half of ADRs 
are (at least potentially) preventable although preventability is 
much easier to diagnose in hindsight. However, interventions 
that reduce the probability of an ADR occurring can be an 
important way to reduce the risk of patient harm. 
 There are two basic steps that can be following to prevent an 
ADR occurring: 
 1  identify the subgroup of patients who are likely to be 
susceptible to the adverse effect and modify the treatment 
choice accordingly 
 2  ensure the treatment plan mitigates any possible adverse 
effects. 
 Identifying susceptibility 
 Knowledge of patient susceptibilities can inform your 
prescribing decision and reduce the risk of an ADR. A 
patient's medication history will identify any previous ADRs 
and therefore preclude re-exposure to the drug. In other 
cases, susceptibility factors such as age, gender, pregnancy 
status and ethnicity can help predict the risk of an ADR 
occurring. For example, National Institute for Health 
and Care Excellence guidance has suggested that patients 
of African or Caribbean descent should be prescribed an 
angiotensin-II receptor blocker in favour of an angiotensin 
converting enzyme (ACE) inhibitor for hypertension 
because of the risk of ACE inhibitor-induced angioedema. 
Pharmacogenetics is starting to yield more personalised 
medicine choices by predicting who is more susceptible to 
suffer a specific ADR (Table  1 ). 
 Clinical decision support systems available at the point of 
care can inform practitioners of any patient specific cautions 
to treatment or additional monitoring requirements to reduce 
the risk of harm. A detailed discussion is beyond the remit of 
this paper, but practitioners should not rely on decision support 
as systems vary widely in their provision of information from 
absence of relevant alerts to information overload leading to 
alert fatigue. 
 Treatment plan 
 Prudent, safe prescribing is key to reducing errors that can 
contribute to ADRs. Treatment plans should consider and 
mitigate for any possible adverse effects. 11 For example, co-
prescription of folic acid with methotrexate will reduce the 
incidence of adverse effects associated with folate deficiency; 
and monitoring electrolytes and renal function when treating 
with renally active drugs or diuretics. These examples can 
all prevent treatment-emergent adverse effects although 
may be limited because monitoring recommendations are 
often inadequate or ambiguous. It is important to remember 
that prudent prescribing may also avoid the use of drugs 
altogether and the treatment plan should always consider non-
pharmacological or conservative options. 
 Overall a systems approach, involving multiple strategies 
and including the patient and all healthcare professionals, 
is required to reduce the risk of an ADR and prevent those 
‘avoidable’ reactions occurring in practice. 12 
 Table 1.  Examples of pharmacogenetic susceptibility for drug-specific adverse drug reactions. 
Drug/drug class Pharmacogenetic 
marker 
Additional susceptibility factors Example of clinical context 
Carbamazepine Han-Chinese, Thai and Malaysian 
populations
Marker for carbamazepine-induced Stevens-
Johnson syndrome and toxic epidermal necrolysis
Simvastatin Advanced age, untreated 
hypothyroidism, excess physical activity, 
concomitant medications (eg fibrates)
Statin-induced rhabdomyolysis (rare) whose risk 
is four times greater with single defective allele, 
16 times greater with two defective alleles
Abacavir Higher CD8 cell count at start of 
therapy
Marker for abacavir-induced hypersensitivity 
reactions with fever, rash, lethargy and abdominal 
and acute respiratory symptoms
Thiopurines 
(Azathioprine and 
mercaptopurine)
 HLA B*15:02 (in the 
populations listed)
SLCO1B1 (solute 
carrier organic anion 
transporter 1B1)
HLA-B*57:01
Thiopurine Methyl 
Transferase Activity
N/A 1 in 10 individuals are heterozygous (50% 
normal TPMT activity) and 1 in 300 have 
completely deficient activity. Thiopurine-induced 
myelosuppression is associated with TPMT activity.
 N/A = not applicable; TPMT = XXX 
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 Diagnosing adverse drug reactions 
 ADRs are one of the great mimics in healthcare, often 
emulating ‘traditional diseases’ and manifesting in all 
systems of the body. Drug-related problems in patients 
admitted to hospital may present in many different 
ways, including weakness or drowsiness, biochemical or 
haematological derangements (such as acute kidney injury, 
electrolyte imbalance or anaemia), bleeding, gastrointestinal 
disturbances, hypoglycaemia or healthcare-associated 
infections such as  Clostridium difficile . However, rarer 
manifestations – such as drug-induced lupus, fixed drug 
eruptions, drug-induced eosinophilia or angioedema – 
require a level of vigilance and suspicion on behalf of the 
clinician who should look very hard to identify a causative 
agent. A comprehensive medication history is fundamental 
in identifying any possible connection between a presenting 
complaint or subsequent finding and an ADR, as well 
as preventing future ADRs. Various criteria can help in 
attributing causality to a particular drug (Table  2 ). 13 
 In some cases, specific investigations can assist in the 
diagnosis of an ADR by providing objective evidence of the 
reaction and confirming a drug-induced disease. For example, 
organ-specific damage accompanied by intracellular tissue 
deposition of the drug or a metabolite (eg indinavir crystalluria 
and nephropathy). 14 
 Pharmacovigilance 
 Pharmacovigilance is defined as ‘the science and activities 
relating to the detection, assessment, understanding and 
prevention of adverse events or any other drug-related 
problem’. 15 
 New legislation was introduced in the European Union in 
2012 to ensure good vigilance practice for pharmaceutical 
companies and the medicines regulators. This new guidance 
clearly identifies the roles and responsibilities of relevant 
stakeholders in terms of drug safety. Notably, the guidance has 
introduced a programme of more intensive surveillance for 
new pharmacological agents and biological agents with black 
triangle status (ie those requiring additional monitoring). 
One of the guiding principles is that the pro-active strategies 
of the risk management policy replace the previous reactive 
strategies. 
 Reporting of adverse drug reactions 
 The mainstay of detecting potential ADRs over the last half a 
century has been spontaneous reporting systems such as the 
Yellow Card Scheme in the UK, operated by the Medicines 
and Healthcare Products Regulatory Agency (MHRA) and the 
Commission on Human Medicines (CHM). The scheme was 
founded in 1964 following the thalidomide disaster in the late 
1950s. Through spontaneous reporting, the scheme collects 
data of suspected ADRs related to all licensed and unlicensed 
medicines and vaccines, including those issued on prescription 
or purchased over-the-counter. For a report to be valid, only 
four items of information are required: an identifiable patient, 
a reaction, a suspected medicinal product and an identifiable 
reporter. However, reporters are encouraged to provide as 
much information as possible, ie to provide additional data 
and clinical context for assessors. The UK scheme continues 
to receive in the region of 25,000 reports per year and provides 
the medicine regulators an insight into the occurrence of 
ADRs. Unfortunately, underreporting remains a key challenge, 
with fewer than 5% of all ADRs estimated as being reported 
in practice. This limits the ability of systems to give accurate 
incidence data. In 2014, NHS England and the MHRA issued 
a joint alert:  Improving medication error incident reporting 
and learning . As part of this, ADRs occurring as a result of 
medication errors reported to the National Reporting and 
Learning System (NRLS) will automatically be reported to the 
Yellow Card Scheme. 
 Patients are increasingly involved in their own therapeutic 
management and, because an early assessment of patient 
Yellow Card reporting proved the value of this approach, 16 
all patients are now actively encouraged to report ADRs. 
Paper reports (on the original yellow cards) have largely been 
superseded by online reporting systems or use of the Yellow 
Card app. Electronic health records used in general practice 
and in some hospitals can also include integrated reporting 
that sends data on ADRs directly to central agencies for 
processing before entry into national and international 
databases. 
 Spontaneous reporting systems, while widely adopted for 
pharmacovigilance, are most effective when the adverse events 
are rare and uncommon (less than 1% of treated patients) 
and when the event is typical of a drug-induced condition (eg 
 Table 2.  Medication history elements that may 
assist clinical assessment of adverse drug reaction 
(ADR) probability. 
Question Clinical relevance 
Have you taken the 
medication before without 
adverse effects?
Prior drug exposure doesn’t 
entirely rule out an ADR, although 
tolerating treatment previously 
may make hypersusceptibility 
reactions less likely
Did anything else change 
around the time of 
possible ADR other than 
the suspected drug (eg 
other treatments, over-the-
counter medicines, disease 
progression)
Examination of whether there 
are alternative causes (other than 
the suspected drug) that could 
on their own have caused the 
reaction
Did the reaction occur only 
after the drug was started?
While not all ADRs occur 
immediately or early in therapy 
(ie on drug challenge), an effect 
occurring before drug exposure is 
good counter evidence
Did the reaction resolve 
when the drug was 
stopped (or when a specific 
treatment was given)?
Effects that disappear 
when treatment is stopped 
(de-challenge) may increase 
suspicion of an ADR unless an 
irreversible reaction
Was there ever intentional 
or accidental use of the 
drug following an ADR?
An ADR occurring on re-exposure 
to a drug increases the probability 
of a causal relationship
 Based on original criteria described by Naranjo  et al (1981). 12 
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 Conclusion 
 Herein we have discussed the identification, management 
and reporting of ADRs. We have described how modern 
technology is changing the way that ADRs are predicted, 
prevented, detected and managed, and how we continue to 
try and improve these processes with technological advances. 
Individualised therapy is becoming more of a possibility as not 
just pharmacogenetics but other phenotypic information can 
be combined to generate patient-specific advice to prescribers. 
Such regulatory science at national and international level 
can help achieve a positive benefit-to-harm ratio throughout 
the lifecycle of a medicinal product. For individual clinicians, 
achieving the best outcomes from therapies remains a key goal 
because avoiding or mitigating the risk of ADRs continues to 
challenge our everyday clinical practice. ■
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